MIORG logo MIORG Investor Deck
Back to investors page Contact MIORG
Title 01
MIORG logo

MIORG Oy

Reverse translational immuno-oncology for partnering-ready therapeutic and diagnostic assets.

Finnish preclinical biotech Therapeutic peptides and mAbs Companion diagnostics
Corporate overview
  • Reverse translational precision oncology platform centered on immune-resistance biology in human tumors.
  • Programs advanced through target discovery, validation, therapeutic design, and preclinical proof-of-concept.
  • Business model focused on partnering-ready assets for licensing, collaboration, and broader pharmaceutical development.
Problem 02

Cancer immunotherapy resistance remains a major unmet need.

Immune checkpoint therapy changed oncology, but durable benefit remains constrained by cold tumors, immune-desert states, poor tumor immunogenicity, and disrupted innate-adaptive immune crosstalk that prevents effective antitumor responses.

Cold tumors

Many tumors remain poorly infiltrated or functionally inaccessible to effective antitumor immunity.

Biology gap

Mechanisms that actively suppress immune control are not always captured by conventional discovery workflows.

Therapeutic opportunity

Mechanism-based assets can create new combination logic and new routes to restoring antitumor immune activity.

Solution 03

From patient-derived discovery to partnering-ready assets

MIORG uses reverse translational precision oncology to start from human tumor biology, build more assertive preclinical programs, and create value before clinical execution.

MIORG-driven preclinical value creation

MIORG starts with patient-derived discovery and advances assets through target validation, therapeutic design, functional and in vivo proof-of-concept, and IND-enabling / partnering preparation.

Patient-derived discovery

Human tumor biology, biospecimens, resistance phenotypes.

Target validation

Functional validation of actionable resistance biology.

Therapeutic design

Peptides, antibodies, and diagnostic-linked strategies.

Functional & in vivo PoC

Mechanism, immune restoration, tumor-model evidence.

IND-enabling / Partnering

Preclinical package, licensing, pharma partnering.

MIORG value inflection point
Preclinical PoC / IND-enabling / partnering-ready asset
Downstream partner-led development

Clinical development is shown to contextualize the full drug lifecycle; MIORG’s primary business model is preclinical asset generation and partnering.

Phase 1

First-in-human safety and dose escalation.

Phase 2

Efficacy signal and dose optimization.

Phase 3

Large-scale efficacy and safety confirmation.

Regulatory approval

Submission, review, approval.

Commercial launch

Market access, reimbursement, commercialization.

Value creation model Create value before clinical execution — convert resistance biology into partnering-ready preclinical assets.
Workflow 04

Platform workflow

A translation model built to move efficiently from patient-derived biology to partnering-ready preclinical packages.

1

Patient-derived discovery

Clinically annotated biospecimens and translational datasets reveal resistance mechanisms in tumors.

2

Target validation

Systems immunology and functional testing confirm biological relevance and tractability.

3

Therapeutic design

Programs are translated into peptide, antibody, and biomarker-guided therapeutic strategies.

4

Functional and in vivo PoC

Programs advance through mechanism-driven preclinical experiments and efficacy-supporting models.

5

Partnering pathway

Selected assets are positioned for licensing, partnering, or progression into broader development paths.

Therapeutic pipeline 05

Therapeutic pipeline

Program Modality Indication Stage Positioning
Invaritin (MIO-7436) Therapeutic peptide Cutaneous melanoma In vivo PoC Antigen-presentation-associated immune resistance
MIO-36 Monoclonal antibody Cutaneous melanoma and solid tumors In vivo PoC / Lead Optimization Innate immune engagement to drive adaptive antitumor immunity
Nexorin (MIO-7071) Therapeutic peptide Melanoma and solid tumors Discovery Immune-receptor-associated resistance
Nexlimomab (MIO-7072) Monoclonal antibody Melanoma and solid tumors Discovery / Lead Optimization Immune-receptor-associated resistance
Diagnostics pipeline 06

Companion diagnostics pipeline

Program Type Indication Stage Technology
MIORG PredictMLB Dx (MIO-2101) Companion diagnostic / clinical decision-support tool Cutaneous melanoma, non-small cell lung cancer, and breast cancer Kit development Targeted transcriptomic assay + algorithm
MIORG UvealMet Dx (MIO-5201) Prognostic test Uveal melanoma Model development / retrospective validation Targeted transcriptomic immune-metabolic assay + algorithm
Lead programs 07

Lead programs illustrate the platform’s therapeutic and diagnostic logic.

Therapeutic peptide In vivo PoC

Invaritin (MIO-7436)

  • Designed to modulate antigen-presentation-associated immune resistance.
  • Focused on restoring antitumor immune activity in melanoma contexts.
  • Advancing through optimized preclinical proof-of-concept.
Monoclonal antibody In vivo PoC / Lead Optimization

MIO-36

  • Engages innate immune activity to drive adaptive antitumor immunity.
  • Positioned for rational immunotherapy combinations in cold tumor settings.
  • Advancing through in vivo proof-of-concept and lead optimization.
Diagnostics Kit development

MIORG PredictMLB Dx (MIO-2101)

  • Supports response stratification in metastatic cutaneous melanoma.
  • Uses targeted transcriptomic signatures and algorithmic modeling.
  • Provides a supporting biomarker layer for therapy-focused development.
Diagnostics Model development / retrospective validation

MIORG UvealMet Dx (MIO-5201)

  • Targets prognostic stratification in uveal melanoma.
  • Built around immune-metabolic tumor signatures and algorithmic interpretation.
  • Can create both clinical utility and strategic partnering relevance.
Business model 08

Preclinical asset generation designed for licensing and pharma partnering.

MIORG creates value before clinical execution by moving from patient-derived discovery to functionally validated therapeutic and diagnostic assets with clear partner development pathways.

Patient-derived discovery AI-enabled target discovery Functional validation Molecular design Preclinical assets Pharma partnering
How MIORG creates value
  • Discover immune-resistance targets from patient-derived tumor biology.
  • Validate functional relevance in tumor immunogenicity and antitumor immune responses.
  • Generate therapeutic peptide, monoclonal antibody, and diagnostic assets.
  • Advance selected programs toward partnering-ready preclinical packages.
Partnering outcomes
  • Licensing of individual programs or program families.
  • Therapeutic or diagnostic co-development collaborations.
  • Progression into IND-enabling development with pharmaceutical partners.
  • Program positioning supported by biomarker-informed patient selection logic.
Market evaluation 09

Large oncology markets are converging around immunotherapy, biomarkers, and AI-enabled discovery.

Oncology drugs US$294.01bn

Projected worldwide oncology drugs revenue by 2030, up from US$232.50bn in 2026.

Cancer immunotherapy US$231.3bn

Projected global cancer immunotherapy market size by 2031, compared with US$83.6bn in 2023.

AI drug discovery US$20.04bn

Projected global AI drug discovery market size by 2032, supporting faster asset generation.

Selected growth signals
Oncology drugs
2026 US$232.50bn 2030 US$294.01bn
Cancer immunotherapy
2023 US$83.6bn 2031 US$231.3bn
IO assays
2024 US$5.0bn 2031 US$10.5bn
Why this matters for MIORG
  • Immunotherapy resistance creates demand for rational combinations that expand responder populations.
  • Biomarker-guided development supports clearer patient-selection and partnering logic.
  • AI-enabled discovery and molecular design can improve preclinical asset generation efficiency.
Founder and team 10

MIORG team

Founder-led translational immuno-oncology supported by scientific, clinical, business, and strategic advisory expertise relevant to preclinical asset generation and pharma partnering.

Management

Scientific leadership, partnerships, and commercial perspective supporting MIORG’s execution model.

Founder & Scientific Director

Cancer immunology, reverse translational precision oncology, therapeutic and diagnostic program leadership.

Scientific strategy Program leadership

Head of Strategic Partnerships & Co-Founder

Strategic partnerships, stakeholder engagement, behavioral science, operations and growth support.

Partnerships Growth support

Business Development & Market Intelligence

Market research, customer acquisition, investor relations, and growth strategy.

Market strategy Investor relations

Chief Scientific Officer

Scientific program development, translational research strategy, and preclinical execution support.

Research programs Preclinical execution
Scientific, Clinical & Business Advisors

External expertise spanning pathology, translational medicine, clinical strategy, fundraising, and governance.

Senior Advisor, Translational Pathology

Clinical pathology, translational oncology, biomarker validation, and tissue pathology strategy.

Clinical Advisor (UK and EU)

Clinical oncology and translational immuno-oncology guidance.

Clinical Advisor (USA)

Melanoma-focused clinical insight and therapeutic development perspective.

Senior Advisor, Translational Medicine

Translational medicine, biomarker strategy, and immune profiling perspective.

Fundraising Advisor

Financing strategy and investor-facing development support.

Advisor, Growth & Investment Strategy

Growth planning, investment strategy, and external positioning.

Advisor, Corporate Strategy & Governance

Corporate strategy, governance, and scaling perspective.

Milestones 11

Near-term milestones

Therapeutic advancement

Advance selected peptide and monoclonal antibody programs through functional and in vivo proof-of-concept.

Diagnostic validation

Continue retrospective validation, assay refinement, and positioning of transcriptomic diagnostic tools for partnering.

Partnering readiness

Build data packages that support investor discussions, strategic collaborations, and later-stage preclinical development planning.

Contact 12

Partnering and investor contact

MIORG welcomes conversations with investors, pharmaceutical companies, diagnostic partners, and translational collaborators interested in preclinical immunotherapy assets and reverse translational oncology.

[email protected] Turku, Finland
Discussion areas
  • Therapeutic program partnering
  • Diagnostic collaboration
  • Investor outreach
  • Preclinical development strategy